We conducted linear regression analysis of the Pathway_ranks over the past 10 years of each pathway, and pathways exhibiting a statistically significant upward trend ( P 0.5
Las principales son Wegovy (para obesidad), Mounjaro (ms eficaz segn estudios) y Saxenda
Key tips for underwriting applicants with GLP1 use Immediately look for: Evidence of the underlying diagnosis (as seen in medical claims, EHR, APS) Whether the GLP-1 is FDA-approved or off-label for that condition Signs of medication adherence (12 months, regular fills) Get cautious when: A GLP1 appears without any supporting clinical context Fills are intermittent or recently initiated Theres no alignment between the medication and expected companion therapies (e.g., no CPAP with sleep apnea) Be confident when: The diagnosis is clear The drug is first line and clinically appropriate Use has been stable long enough to confer benefit Kyle Schimek, PharmD Kyle Schimek is a board-certified pharmacist and Clinical Services Manager at Milliman IntelliScript

Studies show that CrAT overexpression in primary human skeletal myocytes increases glucose uptake and attenuates lipid-induced suppression of glucose oxidation, demonstrating the importance of carnitine-dependent metabolic pathways in preserving insulin sensitivity and metabolic health
98,99 However, in some patients, discontinuation of amantadine appears to cause a rebound worsening of dyskinesias to an even higher intensity than before its introduction
Semaglutide is a GLP-1 receptor agonist (the active ingredient in Wegovy and Ozempic)